Target will sell its pharmacy and clinic businesses to CVS Health in the latest twist behind a push from big retailers to become all things to all customers.
The nation’s second-largest drugstore chain will pay about $1.9 billion to run Target’s in-store health operations and expand what they offer for customers who have come to expect that they will be able to fill a prescription when they shop at Target.
If approved by regulators, this could be a savvy deal for CVS as it gains access to customers at 1,700 established locations without having to do heavy construction.
That said, the deal will take away Target as a competitor in the pharmacy market, which could draw some antitrust scrutiny from regulators.
Full content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Regulators Probe SES-Intelsat Deal, Seek Insight on Starlink’s Competitive Threat
May 12, 2025 by
CPI
Trump Removes Copyright and Library of Congress Leaders After AI Policy Rift
May 12, 2025 by
CPI
Delta, Korean Air Buy Into WestJet in Major Cross-Border Deal
May 12, 2025 by
CPI
Trump Targets Big Pharma With Tough New Drug Pricing Rules
May 12, 2025 by
CPI
Geradin Partners Expands London Team with New Partner Hire
May 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece